Docetaxel use associated with significant reduction in prostate cancer death in very poor prognostic group

Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis. The question remains as to whether the chemotherapy drug docetaxel, which increases survival in metastatic prostate cancer, can improve the cure rate in these patients.

Leave A Comment

Your email address will not be published. Required fields are marked *